In the large, randomized, double-blind PARADIGM-HF trial, LCZ696 treatment has been shown to promote significant benefits in patients with chronic heart failure, when compared to angiotensin-converting enzyme inhibition (enalapril) (McMurray et al., 2014). Here, ACE is linked to congestive heart failure.